• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Allogeneic CRISPR Hybrid RNA-DNA Gene Editing Cell Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs offers cutting-edge allogeneic CRISPR hybrid RNA-DNA gene editing chimeric antigen receptor T (CAR-T) cell development service, allowing for precise and efficient genetic modification of immune cells for therapeutic applications. By harnessing the power of CRISPR technology, we tailor CAR-T cells to target specific antigens, enhancing their efficacy and reducing off-target effects. Our team of experts specializes in the development of allogeneic CAR-T cell therapies, offering a comprehensive and customizable approach to gene editing that meets the unique needs of our clients.

CRISPR Hybrid RNA-DNA Gene Editing: Next-generation CRISPR Technology

CRISPR hybrid RNA-DNA gene editing is a cutting-edge technology that combines the precision of CRISPR-Cas9 gene editing with the versatility of RNA-guided editing. In this approach, a synthetic guide RNA molecule is designed to target a specific gene sequence in the DNA, allowing the Cas9 protein to make precise cuts and edits to the gene. One of the key advantages of CRISPR hybrid RNA-DNA gene editing is its ability to target specific sequences within the genome with high precision, allowing for more accurate and efficient gene editing.

Fig.1 Applications of CRISPR technology on CAR-T cells.¹

Allogeneic CRISPR Hybrid RNA-DNA Gene Editing CAR-T Cell Development Service at Creative Biolabs

Creative Biolabs offers the allogeneic CRISPR hybrid RNA-DNA gene editing CAR-T cell development service which combines cutting-edge gene editing technology with the powerful immune cell therapy approach of CAR-T cells. With our service, we can modify T cells using a combination of CRISPR gene editing tools, including both RNA and DNA-based approaches, to precisely target and edit specific genes of interest. This enables the creation of engineered CAR-T cells with enhanced therapeutic properties, such as improved targeting of tumor cells and increased persistence and efficacy in the body.

Workflow of Our Service

The workflow for the Allogeneic CRISPR Hybridization RNA-DNA Gene Editing CAR-T Cell Development Service begins with sample collection, followed by isolation and manipulation of T cells to express CARs. Next, allogeneic CRISPR hybrid RNA-DNA gene editing technology was used to precisely edit and modify T cells to enhance their anti-tumor activity. The edited CAR-T cells are then expanded in culture to reach therapeutic doses, and then subjected to rigorous quality control testing to ensure safety and efficacy.

Advantages of Our Service

• Increased efficiency: Allogeneic CRISPR hybrid RNA-DNA gene editing allows for precise and efficient modifications to be made to the CAR-T cells, resulting in enhanced therapeutic potential.
• Reduced immune response: By using allogeneic CRISPR gene editing, the risk of immune rejection is minimized as the cells are modified to be more compatible with the patient's immune system.
• Customized modifications: The hybrid RNA-DNA approach offers a high degree of customization, allowing for specific genetic modifications to be made to the CAR-T cells based on the patient's individual needs.
• Reduced off-target effects: Allogeneic CRISPR gene editing helps to minimize off-target effects, ensuring that the modified CAR-T cells target cancer cells more specifically without causing harm to healthy tissues.

Contact Us

If you are interested in exploring the cutting-edge technology of Allogeneic CRISPR Hybrid RNA-DNA Gene Editing CAR-T Cell Development, we invite you to contact us now to learn more about our innovative services. Our team of experts is dedicated to providing you with top-notch service and support throughout the entire process. Whether you have questions or are ready to get started on your project, we are here to help. Reach out to us now to begin your journey toward innovative and cutting-edge cell development solutions.

Reference

1. Wei, Wei et al. "CRISPR/Cas9: A powerful strategy to improve CAR-T cell persistence." International journal of molecular sciences vol. 24,15 12317.